Suspension Of Fenspiride Medicines Due To Potential Risk Of Heart Rhythm Problems
On January 15, 2019 EMA's Pharmacovigilance Risk Assessment Committee recommended an EU-wide suspension of fenspiride medicines due to the risk of QT prolongation and torsades de pointes ...
European UnionFood, Drugs, Healthcare, Life Sciences